Your browser doesn't support javascript.
loading
Atlas of Metastatic Gastric Cancer Links Ferroptosis to Disease Progression and Immunotherapy Response.
Cheng, Xiangdong; Dai, Enyu; Wu, Jibo; Flores, Natasha M; Chu, Yanshuo; Wang, Ruiping; Dang, Minghao; Xu, Zhiyuan; Han, Guangchun; Liu, Yunhe; Chatterjee, Deyali; Hu, Can; Ying, Jieer; Du, Yian; Yang, Litao; Guan, Xiaoqing; Mo, Shaowei; Cao, Xuanye; Pei, Guangsheng; Jiang, Jiahui; Lu, Xiaoyin; Benitez, Ana Morales; Waters, Rebecca E; Pizzi, Melissa Pool; Shanbhag, Namita; Fan, Yibo; Peng, Fuduan; Hanash, Samir M; Calin, George; Futreal, Andrew; Song, Shumei; Yee, Cassian; Mazur, Pawel K; Qin, Jiang-Jiang; Ajani, Jaffer A; Wang, Linghua.
Affiliation
  • Cheng X; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China; Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Dai E; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wu J; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Flores NM; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Chu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dang M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Xu Z; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
  • Han G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Liu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Chatterjee D; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hu C; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
  • Ying J; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
  • Du Y; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
  • Yang L; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
  • Guan X; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
  • Mo S; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
  • Cao X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pei G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jiang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lu X; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Benitez AM; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Waters RE; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pizzi MP; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shanbhag N; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fan Y; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Peng F; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hanash SM; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Calin G; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Song S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yee C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Solid Tumor Cell Therapy Program, The University of Texas MD Anderson Cancer Center,
  • Mazur PK; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: PKMazur@mdanderson.org.
  • Qin JJ; Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China; Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, Zhejiang, China. Electronic address: jqin@ucas.ac.cn.
  • Ajani JA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jajani@mdanderson.org.
  • Wang L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, Texas. Electronic address: LWang22@mdanderson.org.
Gastroenterology ; 2024 Aug 02.
Article in En | MEDLINE | ID: mdl-39097198
ABSTRACT
BACKGROUND &

AIMS:

Metastases from gastric adenocarcinoma (GAC) lead to high morbidity and mortality. Developing innovative and effective therapies requires a comprehensive understanding of the tumor and immune biology of advanced GAC. Yet, collecting matched specimens from advanced, treatment-naïve patients with GAC poses a significant challenge, limiting the scope of current research, which has focused predominantly on localized tumors. This gap hinders deeper insight into the metastatic dynamics of GAC.

METHODS:

We performed in-depth single-cell transcriptome and immune profiling on 68 paired, treatment-naïve, primary metastatic tumors to delineate alterations in cancer cells and their tumor microenvironment during metastatic progression. To validate our observations, we conducted comprehensive functional studies both in vitro and in vivo, using cell lines and multiple patient-derived xenograft and novel mouse models of GAC.

RESULTS:

Liver and peritoneal metastases exhibited distinct properties in cancer cells and dynamics of tumor microenvironment phenotypes, supporting the notion that cancer cells and their local tumor microenvironments co-evolve at metastatic sites. Our study also revealed differential activation of cancer meta-programs across metastases. We observed evasion of cancer cell ferroptosis via GPX4 up-regulation during GAC progression. Conditional depletion of Gpx4 or pharmacologic inhibition of ferroptosis resistance significantly attenuated tumor growth and metastatic progression. In addition, ferroptosis-resensitizing treatments augmented the efficacy of chimeric antigen receptor T-cell therapy.

CONCLUSIONS:

This study represents the largest single-cell dataset of metastatic GACs to date. High-resolution mapping of the molecular and cellular dynamics of GAC metastasis has revealed a rationale for targeting ferroptosis defense in combination with chimeric antigen receptor T-cell therapy as a novel therapeutic strategy with potential immense clinical implications.
Key words

Full text: 1 Database: MEDLINE Language: En Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Language: En Year: 2024 Type: Article